BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maraolo AE, Mazzitelli M, Trecarichi EM, Buonomo AR, Torti C, Gentile I. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications. Int J Antimicrob Agents 2020;55:105891. [PMID: 31923569 DOI: 10.1016/j.ijantimicag.2020.105891] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Căpățînă D, Feier B, Hosu O, Tertiș M, Cristea C. Analytical methods for the characterization and diagnosis of infection with Pseudomonas aeruginosa: A critical review. Analytica Chimica Acta 2022. [DOI: 10.1016/j.aca.2022.339696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Criscuolo M, Trecarichi EM. Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences. Antibiotics (Basel) 2020;9:E58. [PMID: 32028615 DOI: 10.3390/antibiotics9020058] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
3 Karlowsky JA, Lob SH, Khan A, Chen WT, Woo PCY, Seto WH, Ip M, Leung S, Wong QW, Chau RWY, DeRyke CA, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019. J Med Microbiol 2022;71. [PMID: 35451945 DOI: 10.1099/jmm.0.001487] [Reference Citation Analysis]
4 Soman R, Bakthavatchalam YD, Nadarajan A, Dwarakanathan HT, Venkatasubramanian R, Veeraraghavan B. Is it time to move away from polymyxins?: evidence and alternatives. Eur J Clin Microbiol Infect Dis 2021;40:461-75. [PMID: 33009595 DOI: 10.1007/s10096-020-04053-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Corcione S, Lupia T, De Rosa FG. Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective. Front Med (Lausanne) 2021;8:617378. [PMID: 34026774 DOI: 10.3389/fmed.2021.617378] [Reference Citation Analysis]
6 Bitar I, Salloum T, Merhi G, Hrabak J, Araj GF, Tokajian S. Genomic Characterization of Mutli-Drug Resistant Pseudomonas aeruginosa Clinical Isolates: Evaluation and Determination of Ceftolozane/Tazobactam Activity and Resistance Mechanisms. Front Cell Infect Microbiol 2022;12:922976. [DOI: 10.3389/fcimb.2022.922976] [Reference Citation Analysis]
7 Principe L, Lupia T, Andriani L, Campanile F, Carcione D, Corcione S, Rosa FGD, Luzzati R, Stroffolini G, Steyde M, Decorti G, Bella SD. Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians. Pharmaceuticals 2022;15:463. [DOI: 10.3390/ph15040463] [Reference Citation Analysis]
8 Bassetti M, Vena A, Battaglini D, Pelosi P, Giacobbe DR. The role of new antimicrobials for Gram-negative infections in daily clinical practice. Curr Opin Infect Dis 2020;33:495-500. [PMID: 33009142 DOI: 10.1097/QCO.0000000000000686] [Reference Citation Analysis]
9 Robben PM, Ayalew MD, Chung KK, Ressner RA. Multi-Drug-Resistant Organisms in Burn Infections. Surg Infect (Larchmt) 2021;22:103-12. [PMID: 32429798 DOI: 10.1089/sur.2020.129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Naga NG, Zaki AA, El-Badan DE, Rateb HS, Ghanem KM, Shaaban MI. Methoxyisoflavan derivative from Trigonella stellata inhibited quorum sensing and virulence factors of Pseudomonas aeruginosa. World J Microbiol Biotechnol 2022;38:156. [PMID: 35798919 DOI: 10.1007/s11274-022-03337-x] [Reference Citation Analysis]
11 Fontana L, Hakki M. Emergence of non-susceptibility during persistent Pseudomonas aeruginosa bacteraemia in haematopoietic cell transplant recipients and haematological malignancy patients. JAC Antimicrob Resist 2021;3:dlab125. [PMID: 34661107 DOI: 10.1093/jacamr/dlab125] [Reference Citation Analysis]
12 Garazzino S, Altieri E, Silvestro E, Pruccoli G, Scolfaro C, Bignamini E. Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data. Front Pediatr 2020;8:173. [PMID: 32432060 DOI: 10.3389/fped.2020.00173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Wang LT, Lin WT, Lai CC, Wang YH, Chen CH, Chang YT, Chen CH, Wang CY. The safety of ceftolozane-tazobactam for the treatment of acute bacterial infections: a systemic review and meta-analysis. Ther Adv Drug Saf 2021;12:20420986211027096. [PMID: 34349976 DOI: 10.1177/20420986211027096] [Reference Citation Analysis]
14 Chahine EB, Dougherty JA, Thornby KA, Guirguis EH. Antibiotic Approvals in the Last Decade: Are We Keeping Up With Resistance? Ann Pharmacother 2021;:10600280211031390. [PMID: 34259076 DOI: 10.1177/10600280211031390] [Reference Citation Analysis]
15 Ronda M, Pérez-Recio S, González Laguna M, Tubau Quintano MF, Llop Talaveron J, Soldevila-Boixader L, Carratalà J, Cuervo G, Padullés A. Ceftolozane/tazobactam for difficult-to-treat Gram-negative infections: A real-world tertiary hospital experience. J Clin Pharm Ther 2022. [PMID: 35255527 DOI: 10.1111/jcpt.13623] [Reference Citation Analysis]
16 Buonomo AR, Maraolo AE, Scotto R, Foggia M, Zappulo E, Congera P, Parente S, Gentile I. Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience. Infection 2020;48:303-7. [PMID: 31981091 DOI: 10.1007/s15010-020-01390-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Saeed MW, Gillani SW, Mahmood RK, Vippadapu P, Hussain MW, Rathore HA, Sipahi OR. A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections. BioMed Research International 2022;2022:1-13. [DOI: 10.1155/2022/1639114] [Reference Citation Analysis]
18 Collignon C, Gana I, Benaboud S, Toubiana J, Castelle M, Oualha M, de Marcellus C. Pharmacokinetics of ceftolozane/tazobactam continuous infusion on renal replacement therapy: A pediatric case report. Therapie 2021:S0040-5957(21)00208-0. [PMID: 34776252 DOI: 10.1016/j.therap.2021.10.003] [Reference Citation Analysis]
19 Zhuang H, Lai CC, Lan SH, Chang SP, Lu LC, Hung SH, Lin WT. Novel β-Lactam/β-Lactamase Inhibitor Combinations versus Alternative Antibiotics in Adults with Hospital-Acquired Pneumonia or Ventilator-Associated Pneumonia: An Integrated Analysis of 3 Randomized Controlled Trials. J Glob Antimicrob Resist 2021:S2213-7165(21)00238-1. [PMID: 34823043 DOI: 10.1016/j.jgar.2021.09.013] [Reference Citation Analysis]
20 Scaglione V, Reale M, Davoli C, Mazzitelli M, Serapide F, Lionello R, La Gamba V, Fusco P, Bruni A, Procopio D, Garofalo E, Longhini F, Marascio N, Peronace C, Giancotti A, Gallo L, Matera G, Liberto MC, Cesana BM, Costa C, Trecarichi EM, Quirino A, Torti C. Prevalence of Antibiotic Resistance Over Time in a Third-Level University Hospital. Microb Drug Resist 2021. [PMID: 34910885 DOI: 10.1089/mdr.2021.0109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]